Press release may 7, 2019
”Lipum is a very interesting company in an exciting development. Soon in the clinical phase and I am looking forward to all challenges ahead of us”, says Pernilla Abrahamsson.
Pernilla Abrahamsson has a PhD in Anesthesia and Intensive Care and is an entrepreneur. She previously invented an advanced medical device for local postoperative sampling. The product enables early detection of complications after surgery, which increases patient safety. Pernilla’s company was acquired by the Nasdaq First North listed company Senzime (Uppsala, Sweden) in year 2015. Since then she has been engaged as product development manager and in marketing and sales.
Lipum has nominated a candidate drug and together with its partner Abzena initiated the cell line development for production of the therapeutic antibody. The intention is to start clinical trials in the beginning of year 2021. The pre-clinical results are very promising and indicate the potential for a completely new mode of action for treatment of chronic inflammatory diseases. Lipum has currently support by European Commission via the Horizon 2020 program and recently raised another 25 MSEK from private investors.
”Pernilla Abrahamsson is perfect for the job. She is entrepreneur-driven and has long experience of life science. We are enthusiastic to welcome her onboard”, says Einar Pontén, CEO.
Contact details
Einar Pontén, CEO
E-mail: einar.ponten@lipum.se
Mobile: +46 70 5783495
Pernilla Abrahamsson, COO
E-mail: pernilla.abrahamsson@lipum.se
Mobile: +46 70 3737472